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Overview
Cardiovasculardisease is the leading cause of death among
American adults. Acute myocardial infarction contributes
substantially to this mortality. National health care statistics
indicate that >675,000 episodes of myocardial infarction
result in hospital admissions in the United States each year
(1), and some sources estimate the actual number of episodes
of myocardial infarction to be > 1.3 million per year (2).
In order to modify the morbidity and mortality associated
with infarction, extensive research efforts have been con-
ducted to limit by means of acute interventions, the size,
and hence the impact, of acute myocardial infarction (3,4).
The association between infarct size limitation and im-
proved mortality implicit in this approach has been recently
demonstrated in several clinical trials. When myocardial
reperfusion is achieved by thrombolytic therapy during in-
farction, significant and occasionally dramatic decreases in
short- and long-term mortality have resulted (5-8). How-
ever, this salutary effect is limited to therapy early in the
course of myocardial infarction, as has been extensively
documented in experimental preparations (9). Although a
few investigators suggest that interventions must be initiated
within 2 hours of the onset of symptoms, it is more widely
accepted that intervention may be of benefit if begun within
4 hours (4). Much of the variability in beneficial effects
among clinical studies using similar modes of attempted
infarct limitation can be ascribed to differences in time delay
between symptom onset and intervention (10-12). A recent
large scale study from Italy (7), for example, showed a clear
relation between mortality and the time interval from onset
of symptoms to treatment with thrombolytic agents. There
was a striking reduction in mortality if this interval was < 1
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hour (47%) and a substantial reduction if the interval was
<3 hours. However, there was barely a significant reduction
if this interval was between 3 and 6 hours and no reduction
if it was >6 hours. This relation has important implications
for the risk/benefit ratio of such interventions. Although
thrombolysis administered between 3 and 6 hours after onset
of symptoms improved mortality only minimally even when
large numbers of patients were compared, this benefit may
be clinically insignificant for any given patient although the
same risks are incurred as for those who would more clearly
benefit.
A temporal relation between the time to therapeutic in-
tervention and myocardial salvage has long been suspected,
but this relatively narrow window imposes severe limitations
on the ability of these interventions to address the problem
for which they were designed, namely, the substantial mor-
bidity and mortality associated with myocardial infarction.
Although we are seeing the evolution of potentially more
effective and safe interventions for the treatment of infarc-
tion, these approaches may have only a limited impact on
the morbidity and mortality of infarction given the clinical
reality into which they are being introduced. In practice,
only a small percentage of patients might benefit from such
interventions, even if they were treated by a sophisticated
medical team. The following analysis will detail the reason
for this concern, that currently the overwhelming majority
of patients with myocardial infarction in the United States
would not be acceptable candidates for thrombolytic ther-
apy.
Our Perspective-1987
In mid-1985 we prepared a proposal to enter Phase II of
the Thrombolysis in Myocardial Infarction (TIMI) trial. This
trial is testing the efficacy of several contemporary reper-
fusion therapies, tissue-type plasminogen activator admin-
istration and tissue-type' plasminogen activator administra-
tion followed shortly by coronary angioplasty. We were
eager to join this study and already had experience with
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acute thrombolysis, often followed by angioplasty, in myo-
cardial infarction. We have used such an aggressive ap-
proach, as have many major cardiovascular centers, in se-
lected cases of acute myocardial infarction when considerable
myocardium was believed to be viable but seriously jeop-
ardized. In the absence of randomized, controlled studies,
we relied on our interpretation of evolving clinical research
data to guide us in such decisions for individual patients.
In preparing this proposal we reviewed the recent myo-
cardial infarction experience of our own institution, as well
as that of Phoenixville Hospital, an institution with close
ties to our cardiovascular division. The Lankenau Hospital
is a 450 bed hospital in the city limits of Philadelphia; it
functions as a community hospital as well as a tertiary re-
ferral center, especially in cardiovascular medicine. The
Phoenixville Hospital is a 270 bed community hospital 30
miles north of Philadelphia. There were 478 patients with
a primary diagnosis of acute myocardial infarction in these
two hospitals in the previous 12 months. On the basis of
this number of patients and the TIMI requirement that at
least 75 patients with infarction be randomized per year,
we believed that, even considering the vagaries of patient
enrollment, we could easily surpass the study enrollment
minimums. In order to avoid compromising the proposed
study, we reviewed our myocardial infarction charts to be
certain that all study prerequisites could be met in a sufficient
number of patients.
To our surprise, only 42 (9%) of the 478 patients with
infarction met the eligibility criteria set by the National
Heart, Lung, and Blood Institute for the study. These guide-
lines were not illogically exclusive but rather attempted to
define the population with infarction that might possibly be
helped and probably not harmed by this intervention-in
short, guidelines that would have clinical applicability. Al-
though some patients were excluded because of age >75
years (based on a possible increased incidence of serious
bleeding complications in this age group during thrombol-
ysis), only 11% were excluded solely on this basis. Our 478
patients had a mean age of 66.9 years, similar to the national
mean of 65.8 years for patients experiencing an infarction
(personal communication, Nancy Haase, Data Analyst, Sta-
tistics Specialist, American Heart Association, Dallas, TX),
and thus such age-related exclusions could be expected to
apply equally to the national population of patients with
infarction. Most patients (85% of those excluded) did not
present to the hospital within the time constraint of the study
(3% hours after the onset of symptoms). It should be noted
that this constraint is consistent with the duration of the
"window" for infarct limitation as previously noted. This
limit may in fact be too liberal when it is considered that
our reported timing data relate to time to emergency room
presentation, which is often a much shorter interval than
time to diagnosis, treatment or successful reperfusion in the
case of myocardial infarction.
We considered the possibility that our population, despite
their typical demographics, might in some other way be
atypical. We believed this to be unlikely because our patients
in general come from communities that are receptive to and
insistent on "state of the art" medical care so that unusual
delays in presenting for acute medical care would not be
expected. Previous studies have suggested time delays in
other communities (13-15). Unfortunately, only a minority
of patients with myocardial infarction are available for ther-
apy within 4 hours or even within 2 hours after the onset
of symptoms of infarction. Few acute reperfusion studies
report the number of patients screened to obtain the final
study group, but Khaja et al. (10) reported that only 25%
of their patients with myocardial infarction were considered
eligible for thrombolysis. Murray et al. (16) found that 39%
of their patients with myocardial infarction presented later
than 6 hours (already probably an excessive interval after
the onset of symptoms) and overall only 14% were eligible
for thrombolysis. In the largest study for which such patient
recruitment data are reported (7), the Italian National Study,
which allowed eligibility up to 12 hours after the onset of
symptoms, roughly two-thirds of all patients with infarction
were excluded from entry, more than half of these because
they presented> 12 hours (!) after the onset of symptoms.
The Problem
What is responsible for this delay? Appropriate recog-
nition of the importance and implications of symptoms,
denial and delay in transportation all contribute (13, 14).
Additionally, despite continued progress in rapid patient
triage, considerable delays still exist between emergency
room presentation and diagnosis in patients presenting with
myocardial infarction.
What does this mean for infarct limitation therapies and
studies? That they are worthless or a waste of time and
money? Hardly. It is clear to us that thrombolysis in myo-
cardial infarction can make a significant difference in se-
lected cases, and possibly in general, if rapidly applied. But
timely therapy is a prerequisite, and unfortunately only a
small percentage of patients with infarction will be eligible
for the therapies available now or in the near future. It may
be that little, if anything, can be done to limit myocardial
damage in the majority of patients with myocardial infarc-
tion in the United States unless more effective strategies for
earlier intervention can be developed. Although increasingly
aggressive algorithms are evolving to manage postinfarction
patients with additional myocardium at risk who might ben-
efit from interventions in the peri-infarction period, such
early interventions may not be appropriate for most patients
and do not address the initial pathologic injury of infarction.
What shall our response to this distressing situation be?
Effective treatments have been developed, but practical and
logistic problems limit their application. We hesitate to de-
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fault here to a vague call for better prevention of coronary
disease, although not because we find it ineffective. Actions
by physicians to treat hypertension and by patients to make
life-style changes have contributed significantly to the recent
decline in cardiovascular morbidity and mortality and we
are moving closer to a national consensus on the treatment
of hypercholesterolemia (17), which may offer similar gains.
Such preventive action will certainly not greatly diminish
the frequency of myocardial infarction in the near future,
as changes in sociologic and treatment patterns require many
years to develop, and the amelioration of the infarct-related
morbidity and mortality in 1987 is the subject of this edi-
torial.
The Solutions
Technical developments. These may lengthen the time
interval for successful reperfusion, and new advances in
thrombolysis are being reported with great frequency. Re-
cent studies (18,19) suggest that the therapeutic "window"
in myocardial infarction may extend past the aforementioned
4 hours if thrombolysis is combined with angioplasty. Per-
sistent ischemia due to post-thrombolysis residual stenoses
may be prevented by angioplasty and may compensate in
part for slightly longer initial ischemic episodes. More
"thrombus-specific" thrombolytic agents are being devel-
oped that offer greater efficacy after systemic administra-
tion, perhaps favorably improving both aspects of the
risk/benefit ratio after longer time intervals to treatment (20).
Some new agents can be given by rapid intravenous bolus
injection or intramuscular routes rather than by infusion,
saving valuable minutes during the early course of infarction
(21). Also, some newer agents may have prolonged efficacy,
perhaps minimizing early reocclusion. These advantages
may provide better overall improvement in mortality than
is provided by streptokinase, which does not share these
attributes but has been the agent used in most of the large
infarction intervention studies. Finally, anti-ischemic med-
ications such as beta-receptor blockers or calcium channel
blockers may prolong the time during which reperfusion can
salvage myocardium. But these technical gains will be finite
and possibly quite small, because the temporal development
of myocardial necrosis will not be substantially changed.
Full reperfusion developing between 6 and 12 hours is still
likely to be of marginal importance.
Time delays. The time delays in patient presentation
and treatment can be diminished. Early administration of
thrombolytic agents by specially trained paramedics, a re-
cently reported innovation that may offer significantly better
results than in-hospital thrombolysis (7), has been used in
several other countries. This is one of the simplest ways to
minimize the inevitable delays of patient transport and triage
and will likely be one of the most important means to de-
crease the time to treatment initiation. Previous studies (7)
have shown that paramedics can effectively identify patients
with contraindications to thrombolysis and administer the
drugs to th~ others with acceptable morbidity. Additionally,
although patients with a chest pain syndrome are given
priority in emergency rooms, the time for triage and diag-
nosis, much less treatment, remains unacceptably long in
view of our current knowledge of the brief window of po-
tential myocardial salvage (13,14). Such time intervals can
surely be substantially lessened by more efficient triage.
Patient education. Improved national patient education
will likely help patients to recognize the symptoms of im-
pending myocardial infarction and, more importantly, to
realize the urgent need for prompt treatment. Until now,
we have emphasized to patients only the need to seek med-
ical attention, or to "call the doctor," for symptoms of
coronary ischemia, largely ignoring the urgency for instan-
taneous treatment. With evidence that it is possible to achieve
a 50% reduction in mortality when appropriate treatment is
begun within 1 hour of symptom onset (7), every minute
of procrastination may be important. The impressive re-
ductions in the mortality of myocardial infarction that can
be obtained with such an approach make this education a
high priority for our national.health care expenditures.
Educational programs a~o¥t the dangers of hypertension
and, to a lesser extent, cigarette smoking, set a precedent
for this type of approach. In fapt a few cities, such as Seattle,
have already shown that it i~ possible to successfully im-
prove time to treatment for cardiovascular emergencies by
community-wide education. Such an approach was initially
warranted by the advent of effective means for cardiopul-
monary resuscitation, advanced life support and defibrilla-
tion. There are now additional reasons for reaching patients
at the earliest possible moment of a cardiac emergency. Use
of the full gamut of the information media, including tele-
vision, radio, newspapers and magazines, is warranted. An
active community education program, including speakers,
video presentations and dissemination of information in pub-
lic places, would likely reap dividends. Finally, community
hospitals and medical centers must be involved to extend
these benefits to the maxiIrial number of patients. Such
hospitals, traditionally not involved in clinical research, have
proved to be reliable participants in many trials of acute
myocardial infarction. They can provide more rapid treat-
ment for cardiac events occurring in communities at a dis-
tance from major medical centers. These community hos-
pitals can even develop close professional affiliations with
such a regional center, acting as a "satellite" facility with
resulting mutual benefits. The benefits of prompt intrave-
nous thrombolytic therapy in a satellite community facility
are suggested by Topol et al. (22) in this issue of the Journal.
Conclusions. Thus, we caution the profession about as-
suming immediate blanket application of new technologies
to this all too common and serious problem. Although the
introduction to the Phase I report of the TIMI trial claimed
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that "Acute myocardial infarction . . . . resulted in an es-
timated 676,000 hospital admissions in 1983" in the United
States (20), we must realize that in 1987 only a fraction of
these patients would be eligible for, much less be helped
by, any currently known or proposed intervention. The so-
lution to the substantial problem of the large morbidity and
mortality caused by myocardial infarction is not yet within
easy reach. Although several of the technical aspects of
infarct size reduction have been addressed and in large part
acceptably resolved, it will be more difficult to influence
patient behavior and the health care system's response to
myocardial infarction. The proposals we have outlined are
intended as a first step in the successful resolution of these
remaining problems, which we believe are soluble. The
application of technical advances to a larger percentage of
patients with acute myocardial infarction will be the next
major challenge in this field and should be addressed now.
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